Abstract
Lymphoid neogenesis occurs in tissues targeted by chronic inflammatory processes, such as infection and autoimmunity. In systemic lupus erythematosus (SLE), such structures develop within the kidneys of lupus-prone mice ((NZBXNZW)F1) and are observed in kidney biopsies taken from SLE patients with lupus nephritis (LN). The purpose of this prospective longitudinal animal study was to detect early kidney changes and tertiary lymphoid structures (TLS) using in vivo imaging. Positron emission tomography (PET) by tail vein injection of 18-F-fluoro-2-deoxy-D-glucose (18F-FDG)(PET/FDG) combined with computed tomography (CT) for anatomical localization and single photon emission computed tomography (SPECT) by intraperitoneal injection of 99mTC labeled Albumin Nanocoll (99mTC-Nanocoll) were performed on different disease stages of NZB/W mice (
Keywords
Introduction
Systemic lupus erythematosus is a systemic autoimmune disease characterized by the production of autoantibodies to nuclear self-antigens.1,2 In Lupus nephritis (LN) the formation of immune complexes and their consequent deposition within the kidney causes enhanced inflammation, which leads to disruption of kidney integrity, and development of significant clinical proteinuria.3–7 The resulting proteinuria is often discovered too late to treat and save the kidneys. This can cause acute inflammatory lesions and chronic damage to the kidney and can cause the patient to require lifetime treatment, dialysis, or transplantation.4,5,8,9 To evaluate the progression of LN, a renal biopsy is the gold standard, where a repeated biopsy often is required.10,11 Methods that can detect the early clinically silent events of LN are therefore highly needed.
Positron emission tomography is an in vivo imaging method commonly used in oncological applications, CNS, and cardiovascular imaging. One of the common tracers used in PET is the 18-F-fluoro-2-deoxy-D-glucose (18F-FDG). This tracer is taken up by cells that are highly glycolytic metabolically active. In addition to the neoplastic cells, immune cells, like macrophages and granulocytes, increase their expression of glucose transporters and glycolytic enzymes during phagocytosis.12,13 This makes the use of metabolic PET an interesting method in detecting activated immune cells in vivo.
Lack of a non-invasive diagnostic test, which can diagnose LN at an early stage, is quite evident. In vivo molecular imagings such as PET and SPECT have been used widely to investigate normal and abnormal biological processes in different organs, but little work has been done for the kidney.18–20 The most used PET tracer is 18F-FDG, and different mathematical models of 18F-FDG have been developed to investigate the uptake in different organs.21–23 However, it has been difficult to design a model to evaluate renal FDG-PET data with regards to the complex structure of the kidney and the high excretion of FDG through the kidney.18,24,25
The inflammatory aggregates observed during the progression of murine and human LN are organized into well-defined tertiary lymphoid structures (TLS).26–28 TLS form in tissues that are targeted by chronic inflammatory processes, such as infection and autoimmunity.29,30 We postulate that local events in the kidney, prior to development of proteinuria, are the early but causal process in LN. We hypothesize that TLS formation can be used to detect a silent mesangial nephritis without renal clinical symptoms. Since TLS share similarities with lymph nodes regarding function and structure, 31 the aim of this study was to use the of 18F-FDG in PET and 99mTC Albumin Nanocolloid in SPECT to investigate kidney functionality during SLE disease progression and facilitate the detection of the formation of TLS within the kidney of lupus-prone NZB/W mice, a model of SLE in humans.
Materials and methods
Calculation of sample size
This is a prospective longitudinal animal study. The amount of the animals was calculated based on the “resource equation” method using the equation: E = Total number of animals − Total number of groups. E is the degree of freedom of analysis of variance (ANOVA), and the value of E should lie between 10 and 20 (ref). The minimum number of animals in this study was calculated to be three in each group and maximum four when using six groups of animals.
Animals and grouping
20 BALB/c and 40 (NZBxNZW)F1(NZB/W) mice were purchased from Harlan (Harlan Sprague Dawley Inc, Indiana, USA). Forty-three of the mice were included for PET imaging, 19 mice for SPECT imaging and 16 mice for organ distribution. The Animal Welfare Board, at the UiT–The Arctic University of Norway and the regional ethical committee in Northern Norway approved all procedures (Reference number 6776).
The mice were divided into groups based on age, anti-dsDNA positivity and proteinuria. The groups consisted of 7 weeks old BALB/c (young BALB/c) (
Anti-dsDNA Antibody enzyme-linked immunosorbent assay and measurement of proteinuria
The level of anti-dsDNA antibody in lupus-prone mice serum was measured as described previously. 32 Blood samples were taken every week until positive ELISA test, and thereafter, every second week until proteinuria was detected in urine. The protein in the urine was determined by urine dipstick (Bayer Diagnostics, Bridgend, United Kingdom): 0–1+ (<1 g/L) was regarded as physiological proteinuria; 2+ (≥1–3 g/L) and 3+ (≥3–20 g/L) and 4+ (≥20 g/L). Proteinuria was defined as 4+.
Animal preparation
Mice subjected to 18F-FDG PET/CT imaging were fasted 3 h before acquisition, weighted, and anesthetized. Mice were anesthetized with isoflurane (induction 4% and maintenance 2% in oxygen). To prevent hypothermia, the temperature of the bed was set to 35°C during imaging procedure. For mice undergoing PET/CT imaging, a catheter with 30-gauge needle was placed into the mice lateral tail vein to allow tracer injection.
Imaging
PET, SPECT, and CT imaging were performed by using the TriumphTM LabPET-8TM, 4-detector configuration X-SPECT® small animal PET/SPECT/CT scanner (Trifoil Imaging, Northridge Tri-Modality Imaging, Inc., Chatsworth, CA).
18F-FDG PET/CT imaging
10.57 ± 1.79 MBq 18F-FDG was diluted in 100 μl in sterile saline (
The acquired list mode PET data were histogrammed into 24 × 5 s, 9 × 20 s, and 11 × 5 min, in total 44 time frames, and reconstructed using 3-dimensional maximum likelihood expectation maximization (MLEM) algorithm with 50 iterations. PET images were corrected for varying detector element efficiency, radioactive decay, random coincidences, dead time losses, attenuation, and scatter, before a dose calibration factor was applied, to convert the output images into the unit of MBq/cm3. CT raw data were reconstructed using filtered back projection algorithm.
99mTC-Nanocoll SPECT/CT imaging
Mice were anesthetized as described above and injected intraperitoneally (i.p.) with 99mTC-Nanocoll (mean dose activity 56.37 MBq ± 9.1 MBq) diluted in sterile saline (100 μl maximum injection volume). Dynamic SPECT scans (60 min, 4 × 15 min time frames) started 12 ± 9 min post tracer injection. Acquisition was performed with 90° rotation, to cover one revolution with the four SPECT detectors, 16 × 4 projections, five multipinhole collimator (N5F75A10), and 45 mm radius of rotation. The images were reconstructed using ordered subset expectation maximization algorithm (eight subsets and five iterations). A CT scan was performed after SPECT acquisition, with identical acquisition parameters as for PET imaging, described above.
Data analysis of in vivo imaging
Kinetic analysis of PET data
Images were analyzed using PMOD (PMOD Technologies Ltd., Zürich). Volumes of interests representing whole kidney, cortex, and renal hilum were delineated in the CT images, and VOIs representing bladder were drawn in the PET images. These VOIs were outlined semi-automatically (60% isocontour of the maximal voxel value). 18F-FDG blood concentrations were obtained from the vena cava VOI (1 mm3). This VOI was selected by finding the voxel with highest activity in the first 5–10 s of the PET scan (first or second time frame). Volumes of interest data were converted to standardized uptake value (SUV) g∗min/ml) by normalizing to injection dose per animal weight. The area-under-curve (AUC) was calculated for renal hilum, cortex, and kidney tissue regions based on the measured time activity curves from each segmented region in the dynamic PET data.
Three-compartment model
A three-compartment model, based on work done by Qiao et al.,
18
was implemented in an in-house developed MATLAB script (Mathworks, USA) (Figure 1a). The model equation is given by Renal hilum SUV increased in anti-dsDNA Ab+ mice. (a) Illustrates the three-compartment model. 
Five-compartment model
The five-compartment model (Figure 2a), described by Garbarino et al.,
33
consists of Filtration of 18F-FDG by glomeruli was lower in lupus-prone mice producing anti-dsDNA Ab. (a) Illustrates the five-compartment model, where 
The exchange rates are denoted as
SPECT/CT data analysis
The images obtained from 99mTC-Nanocoll dynamic SPECT were visually evaluated by three nuclear medicine
Ex vivo organ biodistribution
The anesthetized animals were euthanized by cervical dislocation 1 h after 18F-FDG injection. Internal organs were collected, rinsed (2× deionized water), weighted, and measured for radioactivity in an automatic gamma counter (2480 Wizard, PerkinElmer, MA, USA). Organ SUVs were calculated as described above.
Immunohistochemistry
Hematoxylin and eosin (H&E) staining,
Autoradiography
Mice were anesthetized with isoflurane and buprenorphine injected subcutaneously (Temgesic, 0.1 mg/kg body weight). Following 99mTC-Nanocoll SPECT/CT imaging,
Reagents and antibodies
18F-FDG was provided by the University hospital of Northern Norway (UNN)(MAP Medical Technologies, Finland). 99mTC and Nanocoll were purchased from GE Healthcare (USA). CD3 rabbit-anti-mouse (AD452) was purchased from Dako (Denmark)), B220 rat-anti-mouse (MAB1217) from R&D Systems (USA), and F4/80 rat-anti-mouse (122603) was obtained from Biolegend (USA).
Statistical analysis
One-way ANOVA with post-hoc analysis (Dunn’s multiple comparisons test) was performed for PET and SPECT, and unpaired t test was performed on ex vivo organ biodistribution data. A
Results
Decreased glomerular filtration was detected by 18F-FDG PET during early SLE progression
To investigate kidney functionality during SLE disease progression, dynamic PET/CT was performed on different groups of lupus-prone mice (NZBW F1) and control BALB/c mice. The 3CM, using vena cava, kidney, and urine, was used to analyze the data (Figure 1a). Two VOIs, cortex and renal hilum, were defined in kidneys based on the CT (Figure 1b). The
To determine the best possible compartment model to evaluate the kidney functionality during SLE disease progression, data generated through dynamic PET were analyzed by the 5CM (Figure 2a). The
18F-FDG accumulate highly in lymph nodes of anti-dsDNA Ab+ Mice
Ex vivo organ biodistribution studies after dynamic PET were performed on BALB/c ( Histological pictures and ex vivo organ biodistribution. (a) Representative 
99mTC-Nanocoll SPECT can visualize organ-specific TLS
The 99mTC-Nanocoll was used to investigate the presence of TLS in organs of lupus-prone mice at different stages of disease progression. We observed no differences among the total number of VOIs automatically drawn by the software in the different groups, and no differences in the number of VOIs positively accumulating Nanocoll with time among the groups (Figure 4a–d). Through all the positive VOIs within the different groups, only the VOI which was drawn in the pancreatic area varied between groups. The pancreatic VOI was only observed in the dsDNA Ab+ group (6 out of 11 mice), which was selected due to its notable high signal intensity (Figure 4f). We did not observe the same observation in the anti-dsDNA Ab neg and BALB/c groups (Figure 4g). SPECT imaging of pancreatic TLS. (a) SPECT and (b) CT transversal, coronal, and sagittal frames of an example (dsDNA Ab+) showing multiple ROIs generated in Pmod 3.7. A threshold of 75% of the maximum activity was defined for the delineation in all mice. (c) Total number of VOIs accumulating 99mTC-Nanocoll over time in BALB/c, dsDNA Ab- NZB/W, and dsDNA Ab+ NZB/W groups. (d) Relation between total number of VOIs drawn and the number of VOIs that accumulated 99mTC-Nanocoll with time. No differences among the groups could be observed. (e) Atlas representation of kidneys and pancreas in the mouse. (f) Representing a fusion SPECT/CT image of the NZB/W dsDNA Ab+ mouse with a hot spot in the pancreatic area, which could only be observed in NZB/W dsDNA Ab+ mice (
The ex vivo autoradiography following dynamic SPECT was performed to confirm the accumulation of 99mTC-Nanocoll in pancreas of anti-dsDNA Ab+ ( HE staining and immunostaining of TLS in pancreatic tissue in lupus-prone (a)–(c) and BALB/c mice (d). TLS was positively stained for T cells (CD3), B cells (B220), and macrophages (F480). Some TLS was detected near pancreatic islets (black arrows, c). (d) TLS was not detected in pancreatic sections from BALB/c mice. a, artery; d, ducts.
Discussion
In this study, we have performed dynamic PET-CT, SPECT-CT, ex vivo organ biodistribution, and autoradiography on lupus-prone mice at different stages of the disease to develop non-invasive molecular imaging techniques to visualize TLS, measure changes in FDG uptake, and diagnose LN at an early stage. The AUC-SUV for renal hilum and SUV value for k2 (urinary clearance of FDG) increased during LN progression. Hao et al. 18 have reported a decline in the time of FDG clearance in anti-GBM nephritic mice by disease progression, but they did not evaluate the level of FDG clearance regardless of the time. In the 3CM model, the metabolized FDG was neglected based on the small amount compared to FDG in urine or free FDG. 18 In a healthy kidney, it might be correct, but in autoimmune patients with progressive nephritis owing to a large population of cells with high metabolic needs such as activated macrophage, B cell and T cell in the kidney,36,37 the metabolized FDG cannot be ignored. The 3CM model was developed based on human kidneys and regard to the fundamental differences between human and mouse kidney; this model might not be the best choice for evaluating preclinical FDG-PET data.
The majority of previous renal system compartment models have defined two functional compartments, which are anatomically embedded.
33
However, 5CM in this study introduces the tubular (functional and anatomical) and bladder (anatomical) compartments.
33
Garbarino et al.
33
designed the model based on an increase of
Through extensive glomerular damage in LN, the glomerular filtration is disturbed by disease progression.37,38 In the 5CM, the
Systemic lupus erythematosus is an autoimmune disorder, which immune cells in secondary lymphoid organs (SLO), lymph nodes, and spleen are in an active stage. Ex vivo organ biodistribution showed higher FDG accumulation in organs with higher immune cell compositions such as lymph nodes, spleen, and thymus compared to other organs like brain, liver, and lungs. It has been reported that LN patients develop TLS in the kidney,39,40 and based on our finding, anti-dsDNA Ab positive lupus-prone mice develop TLS within the kidney, and when they become proteinuric, a large and organized TLS with germinal center-like structures develop within the kidney.26,28 In this study, we observed higher ex vivo FDG accumulation in the kidney of anti-dsDNA Ab positive groups compared to Ab neg mice, which are in accordance with the presence of large population of metabolic active or activated immune cells. However, the tracer was injected intravenously (i.v.), and it is unclear if this route of administration will reach the developing TLS within the kidney or other organs. Based on our previously published research, the TLS develop in near proximity to the biggest veins and arteries and contain lymph vessels and micro capillaries.26,28 The larger renal drainage lymphatics in mice can be found in the same hilar area.28,41 However, it is still unknown if the blood flow in TLS is connected to the larger vessels. Very little is known about the lymphatic flow within TLS. 42 Based on our results, it seems like the tracer did not reach the TLS. To detect formation of TLS within the kidney, more knowledge about the lymphatics within the kidney and possible injection sites to reach them are needed.
TLS resemble SLO regarding structure, cell composition, and function. 31 Labeled radiotracers up to about 100 nm can enter the lymphatic capillaries and be transported to lymph nodes. 43 More than 95% of the nanocolloidal albumin particles are up to 80 nm, which make them an excellent candidate to study lymph nodes with high uptake rate.44,45 Our data showed accumulation of 99mTC Nanocoll in the lymph nodes and spleen after 1 h. Several studies have reported pancreatic TLS contains T and B cell zones, HEVs, plasma cells, DCs, and HEVs in different mice models.46–49 We demonstrated for the first time that 99mTC Nanocoll accumulated in the pancreas of anti-dsDNA Ab positive NZB/W mice. The TLS within the pancreas was positively immune stained for macrophages, T and B cells, especially those located in the edge of the pancreas. Immune aggregates within the pancreas have been reported in NZB and NZB/W mice. 50 Several studies have previously reported incidences of pancreatitis in SLE patients, 51 and some SLE patients had initial pancreatitis as an early manifestation of the disease. 52 As for the pathogenic role of TLS and pancreatitis in murine SLE, the immune infiltrates were found around the pancreatic ducts, arteries, and veins and not close to the islets. 50 This is not in accordance with our study where TLS was located close to islets. In the previous studies, most of animals and patients had normal glucose levels, and most of the patients responded well to anti-inflammatory treatments. 53 Hence, the development of TLS within the pancreas of lupus-prone mice and SLE patients may reflect the systemic inflammatory disease caused by autoantibody binding in arteries and veins. We could not detect increased uptake of 99mTC Nanocoll in TLS within the kidneys. This could be due to the i.p. injection of the tracer or more likely due to the location of the TLS within the kidneys. Since the mice investigated had large TLS within the kidney, the i.p. injected tracer most likely did not reach the structure. This could be because of the direction of the blood and lymphatic flow within the kidney as discussed for the PET data. However, more studies on TLS formation in SLE are needed.
There are limitations in our study. The 18F FDG tracer has a limitation of use because of the relatively short half-life. This, together with the clearance of tracer by the kidney, makes it difficult to measure and visualize uptake of the tracer within structures of the kidney. In addition, the selected site of injection for both the PET and SPECT tracers may not be optimal for reaching the TLS within the kidney. In rodents, i.p. of macromolecules is typically taken up by the peritoneal lymphatics which directly drain into the thoracic duct and then empties into the venous blood supply. 54 The renal lymphatics are bypassed by this route of administration, and the spleen that filters the blood therefore picks up these nanocolloids and delivers them to the pancreaticosplenic lymphatics, which is where we visualized TLS. Given the organization of the lymphatics with respect to the hemovascular system, the bioavailability to the kidney lymphatics is quite low with i.p. or i.v. administration. TLS have HEVs that are specialized for naive T and B cell entrance, 28 and hence, the blood vasculature may not be an appropriate route for administration for evaluating TLS. Lymph always empties into the blood stream; it is not circulatory but rather unidirectional; and hence TLS identification in the kidney may require more careful consideration of route of administration. Our data indicate that there is a lack of lymphatic watersheds to the kidneys while the spleen lymphatics drain to the pancreatic lymphatics, explaining the tracer uptake within TLS in the pancreas. However, it is still unknown if the use of a long-lived tracer will omit the problem visualizing the uptake of tracer within TLS. The structure of the TLS developing within the kidney is relatively large compared to the whole kidney and is different in cellular density. This opens for the use of magnetic resonance imaging (MRI) in detecting TLS. Either alone or in combination with more specific tracers or appropriate injection sites.
We did not use power calculations to estimate the sample size. However, since it was not possible to assume the standard deviation and the effect size, we used the “resource equation” approach as an alternative approach to the power analysis.
Conclusion
The new 5CM demonstrated a significant change in the uptake of FDG in kidney of non-proteinuric anti-dsDNA Ab positive mice compared to healthy control mice. We were not able to in vivo visualize TLS within the kidney of lupus-prone NZB/W mice neither by PET nor SPECT using i.v. and i.p. injection of 18F FDG and 99mTC Nanocoll, respectively. However, we observed positive uptake of 99mTC Nanocoll by cells within pancreatic TLS. New long-lived specific tracers in combination with MRI, along with optimal injections sites, detecting the formation of TLS, may lead to early detection of LN prior to clinical manifestations.
Supplemental Material
sj-pdf-1-iji-10.1177_20587384211033683 – Supplemental Material for Positron emission tomography and single photon emission computed tomography imaging of tertiary lymphoid structures during the development of lupus nephritis
Supplemental Material, sj-pdf-1-iji-10.1177_20587384211033683 for Positron emission tomography and single photon emission computed tomography imaging of tertiary lymphoid structures during the development of lupus nephritis by Esmaeil S Dorraji, Ana Oteiza, Samuel Kuttner, Montserrat Martin-Armas, Premasany Kanapathippillai, Sara Garbarino, Gustav Kalda, Mara Scussolini, Michele Piana and Kristin A Fenton in International Journal of Immunopathology and Pharmacology
Footnotes
Declaration of conflicting interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this articlse: This project was funded by Northern Norway Regional Health Authority research grant SFP1263-15.
Ethics approval
Ethical approval for this study was obtained from The Animal Welfare Board, at the UiT–The Arctic University of Norway and the regional ethical committee in Northern Norway approved all procedures (Reference number 6776).
Animal welfare
The present study followed international, national, and/or institutional guidelines for humane animal treatment and complied with relevant legislation.
Supplemental material
Supplemental material for this article is available online.
References
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
